ABSTRACT The aim of this study was to determine the dosage and the compounds of arsenic that induce fatty liver in mule ducks and also to investigate their effects on tissue residues. One hundred four ducks, 8 wk old, were randomly selected for one of six dietary treatments in Trial 1 or one of seven dietary treatments in Trial 2. Different levels of roxarsone were administrated: 0, 10, 20, 30, 40, or 50 mg/d, respectively, in Trial 1. In Trial 2, the experimental treatments were of the same level (11.36 mg/d) with different sources of arsenic that included the control without As, roxarsone (3-nitro-4-hydroxyphenylarsonic acid), arsanilic acid, phenylarsonic acid, O-nitrophenylarsonic acid, As 2 O 3 , or As 2 O 5 . Both trials lasted 3 wk, with 1 wk on the treatment followed by 2 wk of withdrawal. Results in Trial 1 showed that a dose of 40 mg roxarsone/d increased liver weight and caused fatty liver, whereas administration of 50 mg/d was lethal. In Trial 2, administration of arsenic (11.36 mg/d) for 1 wk significantly depressed feed intake in the roxarsone, As 2 O 3 , and As 2 O 5 groups (P < 0.05), whereas the treatment significantly decreased only live weight gain in the roxar-
INTRODUCTION
Roxarsone (3-nitro-4-hydroxyphenyllarsonic acid) is an organic arsenical and has been used as a feed additive for half a century. Because roxarsone effectively controls coccidiosis from Eimeria tenella and Eimeria bruneti and improves production performance in poultry (McDougald et al., 1992) , roxarsone combined with ionophores and antibiotics has been widely used in the poultry industry (Waldroup et al., 1995) .
Inclusion of more than 300 mg roxarsone/kg in the diet for 3 to 4 wk causes depressed egg production and fatty liver in laying hens and ducks after 1 or 2 wk of drug withdrawal Chiou et al., 1997) . Fatty liver is a negative factor for egg production in Received February 4, 2000 . Accepted October 26, 2000 To whom correspondence should be addressed: wschiou@dragon. nchu.edu.tw.
295
sone group (P < 0.05). Administration of roxarsone alone increased (P < 0.05) serum cholesterol (CHOL), albumin (ALB), and total protein (TP), whereas only As 2 O 3 among treatments significantly decreased serum triacylglycerol (TG) concentration (P < 0.05). In the roxarsone, arsanilic acid, and phenylarsonic acid groups, serum high density lipoprotein (HDL) decreased to a greater extent (P < 0.05), and arsanilic acid treatment significantly increased the very low density lipoprotein (VLDL) (P < 0.05). After 2 wk of withdrawal, liver weights and relative liver weights were heavier in the treatment groups of roxarsone, As 2 O 3 , and As 2 O 5 as compared to the control (P < 0.05). Levels of CHOL, TG, TP, and ALB were significantly higher in the groups treated with As 2 O 3 or As 2 O 5 as compared to the control (P < 0.05). The roxarsone and arsanilic acid treatments significantly decreased HDL and increased VLDL in plasma (P < 0.05). The creatine kinase (CK) level in the roxarsone, As 2 O 3 , and As 2 O 5 groups was significantly higher compared to the control group (P < 0.05). Among the As sources, roxarsone, As 2 O 3 , and As 2 O 5 caused fatty liver in mule ducks. poultry but is a positive response for the production of a high value product in ducks and geese (Fournier et al., 1997) . It is not clear, however, if roxarsone-induced fatty liver is due to the arsenic content of roxarsone.
The toxicity of arsenic depends on its chemical structure. In general, inorganic arsenic is more toxic than organic arsenic, and the trivalent form is more toxic than the pentavalent form due to lipoate-dependent enzymeblocking activity (Frost, 1967) . The NRC (1980) defined the maximum tolerance of organic arsenic as 100 mg/ kg for poultry and for inorganic arsenic as 50 mg/kg. In fact, the maximum arsenic tolerance in poultry depends upon the arsenic chemical structure and the poultry species. Chronic arsenic toxicity has been found in certain Abbreviation Key: ALB = albumin; AST = aspartate aminotransferase; CHOL = cholesterol; CK = creatine kinase; HDL = high density lipoprotein; LDH = lactate dehydrogenase; LDL = low density lipoprotein; TG = triacylglycerol; TP = total protein; VLDL = very low density lipoprotein. parts of the world. High arsenic content in water depresses animal productivity and causes skin and hair problems in animals and human beings (McDowell, 1992) .
Trials are therefore necessary to determine the effective dose of roxarsone and appropriate arsenicals form, organic or inorganic, that induce fatty liver in mule ducks.
MATERIALS AND METHODS
The mule ducks used in this trial were from a threeway cross with male Peking ducks crossed with female domestic Tsaiya ducks. The female F 1 was crossed with a Muscovy male duck to produce commercial three-way cross mule ducks. One hundred four healthy, 8-wk-old mule ducks with similar live weights were selected and placed into individual cages for the trials. Feed and water were provided ad libitum. The basal diet was formulated according to the nutrient requirements of the NRC (1994) and is presented in Table 1 .
The experiment was conducted with different dosages of roxarsone in the first trial. The second trial included different sources (forms) of arsenic at the same dosage. In both trials, ducks were lavaged with a treatment solution by using a 20-mL pyrex pipette, inserted into the crops of the duck to prevent vomiting. Roxarsone was administrated with equal dosages twice daily (a.m. and p.m.) for 1 wk followed by 2 wk withdrawal. Forty- eight ducks were randomly allocated into six treatment groups for 3 wk in Trial 1. The treatment was a water solution of roxarsone at doses of 0, 10, 20, 30, 40, or 50 mg/d. Therefore we induced fatty livers with different forms of arsenicals, organic and inorganic, with the same level of arsenic in the second trial. The dosage that could induce fatty livers in ducks from Trial 1 was 40 mg/d through drenching equal amounts twice daily. Various chemical forms of arsenic compound that are equivalent to 11.36 mg/d of arsenic were applied in Trial 2. In Trial 2, 56 mule ducks were placed in seven dietary treatment groups. The treatments comprised different forms of arsenic. These included control without arsenic, roxarsone (3-nitro-4-hydroxyphenylarsonic acid; As 28.4%), arsanilic acid (As 34.5%), phenylarsonic acid (As 37.0%), Onitrophenylarsonic acid (As 30.3%), diarsenic trioxide (As 2 O 3 , As 75.7%), and diarsenic pentoxide (As 2 O 5 , As 52.8%).
Feed intake and live weight were individually recorded every week during the experimental periods of both trials. At the end of Trial 1, all ducks were killed, and the liver tissue was preserved in neutral-buffered 10% formalin. The tissues were then embedded in paraffin, sectioned at 6 µm, and stained with hematoxylin and eosin.
Blood samples were taken from the ulnar vein after a 12-h feed withdrawal and water restriction during the first and third weeks of Trial 2. Analysis of blood constituents included concentrations of total protein (TP), albumin (ALB), triacylglycerol (TG), and cholesterol (CHOL) and activities of creatine kinase (CK, 2.7.3.2), aspartate aminotransferase (AST, EC 2.6.1.2), and lactate dehydrogenase (LDH, EC 1.1.1.27) and percentages of high density lipoprotein (HDL), very low density lipoprotein (VLDL), and low density lipoprotein (LDL). At the end of Trial 2, all ducks from each treatment were killed, and abdominal fat and liver samples were taken. Liver slides were prepared for pathological examination. Liver and breast muscle tissue samples were taken for determination of arsenic residue.
Blood serum and TP, ALB, TG, CHOL concentrations were analyzed using an automatic blood chemical analyzer (Gilford system 103 2 ) with Roche testing kits (Roche COBAS MIRA 3 ). The activities of AST, LDH, and CK were measured by kinetic methods as recommended by the German Society for Clinical Chemistry (1972), by using an automatic blood chemical analyzer (Gilford system 103) with Roche testing kits (Roche COBAS MIRA) that measured NADH at 340 nm. Enzyme activities were expressed in international units (U) per liter of serum (Bergmeyer, 1983) . Serum lipoproteins were analyzed according to Houstmuller et al. (1969) using Helena titian gel electrophoresis. An electrophoresis data center scanning densitometer 4 was used to estimate the area of each fraction. The arsenic content of the liver and breast muscle was analyzed by atomic absorption spectrophotometer with a Perkin-Elmer electrodeless discharge lamp (Perkin-Elmer 2380 and FIAS 400 5 ) at the wavelength of 197.7 nm with a slit width of 0.7 nm.
A completely randomized design was applied to examine the effects of levels or chemical forms of arsenic. Variance analyses were calculated using the general linear models procedure of the SAS (1984). Duncan's new multiple-range test was used to compare the means according to Steel and Torrie (1960) . The treatment of 50 mg roxarsone/d was not included in the statistical analysis because only one of eight mule ducks survived.
RESULTS AND DISCUSSION

Experiment 1
Effects of different levels of roxarsone drenching on the growth performance and weight of liver and abdominal fat of the mule ducks are presented in Table 2 . Ducks lavaged with 30 mg/d or more of roxarsone had significantly depressed feed intake (P < 0.05), whereas 40 mg/ d significantly depressed live weight after 1 wk of treatment (P < 0.05). Feed intake and live weight returned to normal levels 2 wk after drug withdrawal. The liver weight and the relative liver weight at the end of the trial were significantly heavier in ducks lavaged with 40 mg roxarsone/d (P < 0.05). Histological examination showed that treatment birds had fatty livers (Figure 1 ). Although 50 mg/d also induced fatty liver, the mortality was also very high (7/8). The symptoms appeared as neck stiffness and drooping head and death after 3 to 4 d of treatment. It appears that the treatment with 40 mg 5 Perkin-Elmer Corp., Analytical Instruments, Norwalk, CT 06859-0012. Chiou et al. (1997) indicated that the inclusion of 312 mg/kg of roxarsone in the diet for 4 wk followed by 1 wk withdrawal caused fatty liver in laying hens. Chen et al. (1997) reported severe fatty liver in laying Tsaiya ducks after 2 wk of drug withdrawal in ducks treated with 300 mg/kg roxarsone for 3 wk. This trial confirmed the findings of Chiou et al. (1997) and Chen et al. (1997) that roxarsone induced fatty liver in mule ducks 2 wk after drug withdrawal. The possible factors that cause roxarsone-induced fatty liver are as follows: 1) the toxic effect of roxarsone, which depresses feed intake during the treatment period, causes an increase in feed intake after withdrawal. Hence, the rate of lipid accumulation is greater than that in the liver. 2) Roxarsone promotes lipogenesis and depresses hepatic lipid mobilization, hence a high lipid accumulation in the liver. Whether the fatty liver in mule ducks was induced by roxarsone or arsenic per se is uncertain because roxarsone is an organic arsenical containing 28.4% arsenic.
Experiment 2
Performance. The growth performance, liver weight, and abdominal fat are presented in Table 3 . After 1 wk of treatment, ducks treated with roxarsone, As 2 O 3 and As 2 O 5 showed a significant decrease in feed intake as compared to the control (P < 0.05), whereas only the roxarsone group had significantly depressed live weights (P < 0.05). The roxarsone, As 2 O 3 , and As 2 O 5 groups consumed relatively more feed than the control 2 wk after drug withdrawal (P < 0.05). The roxarsone, As 2 O 3 , and As 2 O 5 groups had significantly increased liver and relative liver weights (P < 0.05).
In general, inorganic arsenic is more toxic than the organic form (NRC, 1980) . This phenomenon, however, Means in the same row with different superscripts are significantly different (P < 0.05).
1
Per 100 g body weight.
was not observed in the growth performance in this trial. Frost et al. (1955) fed various forms of arsenicals to chickens whose weight ranged from 1,130 to 1,360 g and found that the high maximum tolerance dose was, in order, arsanilic acid, roxarsone, O-nitrophenylarsonic acid, and phenylarsonic acid. Czarnecki et al. (1984) found that As 2 O 3 was more toxic than As 2 O 5 in depressing growth in chickens. We did not observe severe toxic effects from these inorganic arsenics. Effects of As 2 O 3 were more severe than those of As 2 O 5 as inorganic arsenic in the present trial. The results showed that inorganic arsenic significantly depressed feed intake (P < 0.05) without significantly depressing live weight gain (P > 0.05). Among the organic arsenicals, roxarsone showed more toxic effects in the ducks because it significantly depressed feed intake and live weight gains (P < 0.05). Ducks that received roxarsone, As 2 O 3 , or As 2 O 5 treatment had significantly heavier liver weights compared to the controls (P < 0.05) 2 wk after drug withdrawal. The livers of these three treatment groups were also observed to have increased fat, which confirmed the results from Trial 1 in which roxarsone induced fatty liver in the mule ducks. The fatty livers that were induced by three arsenical compounds may be due to the large increase in feed intake during drug withdrawal after depressing feed intake over the treatment period, which caused fat accumulation in the liver. It appears that the effectiveness of arsenic in inducing fatty livers in mule ducks depends upon the chemical form of the arsenic. Table 4 presents the effects of different chemical forms of arsenic on the blood TG, CHOL, and lipoprotein profiles of mule ducks. After 1 wk of drug treatment, ducks receiving roxarsone treatment had significantly in- creased serum CHOL concentration (P < 0.05). Ducks receiving As 2 O 3 had significantly reduced TG concentration (P < 0.05). The serum VLDL in the arsanilic acid group was significantly increased by the drug treatment (P < 0.05). Treatment significantly decreased HDL in the roxarsone, arsanilic acid, and phenylarsonic acid groups (P < 0.05). After 2 wk of drug withdrawal, ducks receiving As 2 O 3 or As 2 O 5 had increased serum CHOL and TG concentrations (P < 0.05), whereas the roxarsone and arsanilic acid groups had significantly reduced serum HDL (P < 0.05) and significantly increased VLDL (P < 0.05).
Lipid Metabolism
Fatty acids are synthesized in the liver in poultry and transported into the blood stream via lipoprotein. In a growing animal, the transported lipoprotein contains mostly HDL with some VLDL and LDL. The lipoprotein is transported into the blood stream and hydrolyzed through lipoprotein lipase into fatty acids and glycerol to provide energy or body storage (Hermier, 1997) . Fournier et al. (1997) indicated that 95% of the fatty liver in the force-fed geese was TG. During fatty liver formation, TG may damage the liver and, hence, depress lipoprotein and decrease TG transport out of the liver. Among the treatments of roxarsone, As 2 O 3 , and As 2 O 5 , which caused fatty liver in this trial, only roxarsone significantly increased VLDL and significantly decreased HDL (P < 0.05), but the other two treatments did not cause any significant effects. This treatment difference implied that the metabolic pathway that induces fatty liver in mule ducks was different for roxarsone, and the inorganic arsenicals and may explain why roxarsone increased the CHOL level during the drug treatment, whereas the inorganic arsenicals increased the CHOL and TG levels during the drug withdrawal period.
Liver Function
The effects of the arsenical source upon the blood constituents, including TP, ALB, AST, LDH, and CK, that relate to liver function are presented in Table 5 . Roxarsone treatment significantly increased the levels of TP and ALB (P < 0.05). The serum AST, LDH, and CK activities in all treatments were within the normal physiological range. After 2 wk of drug withdrawal, TP and ALB levels in the As 2 O 3 and As 2 O 5 treatment groups significantly increased (P < 0.05) compared to the other treatment groups, whereas CK activity significantly increased in the roxarsone, As 2 O 3 and As 2 O 5 treatment groups as compared to the control group (P < 0.05).
Chemicals such as carbon tetrachloride, phosphorus, and heavy metal elements, i.e., lead or arsenic, generally depress protein synthesis in the liver causing fatty livers (Friedman et al., 1970; Mayes, 1973) . Roxarsone is the only treatment that significantly increased TP (P < 0.05) in this trial. After the drug withdrawal period, the As 2 O 3 and As 2 O 5 treatments increased the serum TP and ALB (P < 0.05). The normal range for serum TP in poultry is 3 to 5 g/dL (Beljan et al., 1971) . The highest TP level (5 g/dL) among the treatment groups was the As 2 O 3 group.
Use of specific enzymes to evaluate liver function is currently the most practical approach in most animals except poultry (Lumeij and Wolfswinkel, 1988) . The specific liver enzymes in poultry have not yet been confirmed. Wang (1992) indicated that AST and LDH were widely distributed in the cells of the heart, liver, kidney, and muscle tissues, whereas CK was the specific enzyme for heart and muscle cells. An increase in AST and LDH without an increase in CK may reflect damage in the liver and kidneys. Chen et al. (1997) , on the other hand, demonstrated that an increase in CK and AST (P < 0.05) without an increase in LDH activities occurred after 3 wk of 300 mg/kg roxarsone inclusion in laying Tsaiya ducks. The CK and AST activity increased prominently 2 wk after drug withdrawal. These enzymes did not increase from arsenical inclusion in this trial, which indicates that the treatment did not cause damage in the muscle and liver cells. The increase in CK activity observed in the roxarsone, As 2 O 3 , and As 2 O 5 groups after 2 wk of drug withdrawal represented damage to muscle cells. These three arsenicals also damaged the liver tissue by vascularization of the cells (Figure 1 ) without increasing AST activity. The activity of LDH, on the other hand, significantly increased only in the As 2 O 5 treatment group (P < 0.05). The results of our experiment are in agreement with those of Peh (1990) in which fatty liver induced by forcefeeding of mule ducks did not increase AST or LDH activity.
Arsenic Residue in Tissues
The effects of the arsenicals on breast muscle and liver residues are presented in Table 6 . The arsenic content in the muscle and liver returned to normal levels and did not show significant differences from the control after 2 wk of drug withdrawal (P > 0.05). Chiou et al. (1997) fed laying hens with different levels of roxarsone and observed an increase in the arsenic content in the liver and excreta as compared to the control after 1 wk Means in the same row with different superscripts are significantly different (P < 0.05).
of withdrawal (P < 0.05). This result suggested that a drug withdrawal period of 1 wk is not enough for recovery to a normal level and, hence, would not attain the FDA regulatory standard. Arsanilic acid-treated broilers and swine also returned to normal arsenic content levels in the liver and breast muscle after 1 wk of drug withdrawal (Ferslew and Edds, 1979; Proudfoot et al., 1991) . Underwood (1977) suggested a different path and rate for excretion from the animal body with different arsenic chemical forms. After 2 wk of arsenical withdrawal, the levels of arsenic residues in the liver and breast muscle of mule ducks were less than the 500 ppb maximum tolerance level of FDA regulations (1992) for uncooked muscle.
In conclusion, among organic arsenicals, only roxarsone showed greater toxic effects in ducks. Feed intake and live weight gains were depressed when ducks received roxarsone, As 2 O 3 , or As 2 O 5 treatment. Treated ducks had significantly heavier livers compared to the control (P < 0.05) after 2 wk of drug withdrawal, which indicated that the effectiveness of arsenic in inducing fatty liver in mule ducks depended upon the chemical form of the arsenic. Among the treatments, roxarsone, As 2 O 3 , and As 2 O 5 , which caused fatty liver in this trial, only roxarsone significantly increased VLDL and decreased HDL, whereas the other two treatments did not cause significant effects. This finding implied that the metabolic pathway that induces fatty liver in mule ducks was different for roxarsone from the inorganic arseni-cals. After 2 wk of withdrawal, all arsenic residues in the liver and breast muscle of the mule ducks were lower than the maximum tolerance levels stipulated by FDA regulations.
